Key result
Drug-coated balloons appear to be a promising alternative strategy for acute myocardial infarction, though long-term benefits compared to new-generation drug-eluting stents remain unclear.
Why the study?
Drug-coated balloons are promising for in-stent restenosis and small vessel disease, but their role in acute myocardial infarction remains unclear.
This review summarizes the current evidence regarding the use of drug-coated balloons as a treatment strategy for acute myocardial infarction.
Leaves open the role of drug-coated balloons in acute myocardial infarction; calls for randomized trials to assess long-term outcomes versus stents.
Drug-eluting stents are the standard revascularization strategy for the treatment of symptomatic coronary artery disease. However, in-stent restenosis (ISR), stent thrombosis and reinfarction of target lesions following stent implantation present challenges. Drug-coated balloons (DCBs), which deliver antiproliferative drugs into the vessel wall without stent implantation, are a novel treatment option for percutaneous coronary intervention and have been proven to act as a promising strategy in the treatment of ISR and coronary small vessel disease. However, their role in acute myocardial infarction (AMI) remains unclear. The present review discusses current evidence for the treatment of AMI with DCBs.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2021) conducted a review in Acute myocardial infarction. Drug-coated balloons vs. Drug-eluting stents or bare-metal stents was evaluated. Drug-coated balloons appear to be a promising alternative strategy for acute myocardial infarction, though long-term benefits compared to new-generation drug-eluting stents remain unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: